SCHEMBL2225653

SCHEMBL2225653

COc1ccc(-c2ncc(-c3cccc(Nc4cc(C)ccn4)n3)s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 12/20 0.53
KDR P35968 2/20 0.47
SYK P43405 2/20 0.46
MEN1 O00255 4/20 0.42
RAB9A P51151 4/20 0.42
KMT2A Q03164 4/20 0.42
NPC1 O15118 3/20 0.42
MAPT P10636 1/20 0.42
NFKB1 P19838 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14673453 0.88 KARS1 (0.61) KARS1KDRSYKMEN1RAB9A
SCHEMBL14680949 0.87 KARS1 (0.47) KARS1KDRSYK
SCHEMBL2281477 0.87 RAB9A (0.45) MEN1RAB9AKMT2ANPC1MAPT
SCHEMBL14674189 0.86 KARS1 (0.47) KARS1KDRSYKMEN1RAB9A
SCHEMBL2227939 0.86 RAB9A (0.57) KDRMEN1RAB9AKMT2ANPC1
SCHEMBL2225038 0.85 GAA (0.55) KDRMEN1RAB9AKMT2ANPC1
SCHEMBL2228325 0.85 KARS1 (0.52) KARS1KDRSYKMEN1RAB9A
SCHEMBL13136173 0.84 KARS1 (0.48) KARS1KDRSYKSMN1; SMN2
SCHEMBL2280792 0.83 KARS1 (0.73) KARS1KDRSYKMEN1RAB9A
SCHEMBL2225561 0.83 KARS1 (0.53) KARS1KDRSYKMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK KARS1 1099/4885KDR 79/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.